Leading Product Revenue

February 9, 2024

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2021 (IFRS)	Sales 2022 (IFRS)	Sales 2023(IFRS)
Brand name	Active Ingredient	Indications	Launch Date	Sales 2021 (IFRS)	Sales 2022 (IFRS)	Apr-Dec	Annual (estimated)
Viltepso				7,750	14,341	13,225	18,300
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,059)	(4,139)	(3,332)	(4,800)
(U.S.)				(3,691)	(10,201)	(9,892)	(13,500)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	8,400	10,543	10,024	14,000
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	18,338	15,951	8,329	10,200
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukimia	Aug-2018/ Dec-2022	5,300	4,904	3,692	4,900
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	6,770	5,358	3,142	3,900
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,532	2,938	1,946	2,500
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	4,563	2,649	1,791	2,100
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	4,106	2,826	1,788	2,200
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,128	2,524	1,712	2,300
Erizas	dexamethasone cipecilate	allergic rhinitis	Dec-2009	2,330	2,640	1,038	2,200
Profit in co-promotion				8,934	9,520	6,703	8,800
Revenues from the licensing of industrial property rights				33,207	30,714	28,897	38,000
Pharmaceuticals				120,650	121,988	94,606	125,000
Functional Food				16,834	22,187	18,121	22,000
Revenue				137,484	144,175	112,728	147,000

Brand name	Active Ingredient	Indications	Launch Date	Sales 2021 (IFRS)	Sales 2022 (IFRS)	Sales 2023(IFRS)
Brand name	Active Ingredient	Indications	Launch Date	Sales 2021 (IFRS)	Sales 2022 (IFRS)	Apr-Dec	Annual (estimated)
Viltepso				7,750	14,341	13,225	18,300
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,059)	(4,139)	(3,332)	(4,800)
(U.S.)				(3,691)	(10,201)	(9,892)	(13,500)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	8,400	10,543	10,024	14,000
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	18,338	15,951	8,329	10,200
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukimia	Aug-2018/ Dec-2022	5,300	4,904	3,692	4,900
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	6,770	5,358	3,142	3,900
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,532	2,938	1,946	2,500
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	4,563	2,649	1,791	2,100
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	4,106	2,826	1,788	2,200
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,128	2,524	1,712	2,300
Erizas	dexamethasone cipecilate	allergic rhinitis	Dec-2009	2,330	2,640	1,038	2,200
Profit in co-promotion				8,934	9,520	6,703	8,800
Revenues from the licensing of industrial property rights				33,207	30,714	28,897	38,000
Pharmaceuticals				120,650	121,988	94,606	125,000
Functional Food				16,834	22,187	18,121	22,000
Revenue				137,484	144,175	112,728	147,000

Back Number

Related Link

Nippon Shinyaku’s DNA

Research & Development

Business/Financial Information